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Abstract 
Background: It seems adipocytokines play an important role in breast cancer. Omentin-1 is a novel discovered 
plasma adipocytokine produced mainly in visceral adipose tissue. The aim of present study was to estimate. 
Circulating levels of omentin-1 in postmenopausal breast cancer patients as compare to healthy postmenopausal 
subjects.  
Materials and Methods: This study consisted of 30 postmenopausal women with newly diagnosed breast cancer 
and 30 healthy postmenopausal subjects aged 45 to 70 years. Serum levels of omentin-1 were measured by enzyme-
linked immunosorbent assay.  
Results: The mean age of the case group was 54.3±8.3 years, and the control group was 50.3±3.2 years. The mean 
serum levels of omentin-1 in the case group were 73.1±29.7 ng/mL and in the control group were 108.8±65.4 
ng/mL. The mean serum omentin-1 levels were found to be significantly lower in breast cancer patients (P=0.009). 
We also demonstrated the negative correlation of Omentin-1 with BMI in both groups (p=0.005), however, we did 
not find any association between age and serum omentin-1 levels (P=NS).  
Conclusion: Our studied showed that Omentin-1 level was significantly reduced in the breast cancer patients as 
compare to healthy controls. Decreased omentin-1 levels may contribute to the development of cancer, however 
determination of its role and mechanisms needs more investigations. To sum up, our data suggest that omentin-1 can 
be used as a marker for early detection of breast cancer in postmenopausal women. 
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Breast cancer is the most prevalent type of 
cancer and leading cause of death due to all types of 
cancer in women all over the world. It has been 
reported that breast cancer accounts for 23% of all 
new cancer cases and 14% of all cancer deaths in 
2008 (1, 2). Less than 1% of breast cancers occur in 
women younger than 25 years, but the incidence of 
breast cancer increase sharply after 30 years in whole 
over the world. Whole breast cancer patients in I.R. 
Iran are around 40 thousand and more than seven 
thousand patients are added to this number each year. 
However, data shows an increase in its incidence in 
recent years as most common malignancy among 
Iranian women. Incidence in I.R. Iran is about a 
decade before Countries and more than 30% of 
patients are under 30 years of age (3, 4). As breast 
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cancer prevalence is increasing rapidly. So it is 
important to find predictive factors for early 
detection. Several studies have reported that obesity 
and adipokines increased the risk of postmenopausal 
breast cancer. However the exact mechanisms of 
association between adipokines and cancer is not 
clear (5, 6). 
Over the past decades adipose tissue 
considered as an inactive organ that can only store 
energy, but recently has been introduced as an 
important endocrine organ that produce and secrete a 
number of molecules with biological effects known 
as adipokines such as leptin, adiponectin, visfatin, 
resistin and omentin(6-8). Adipokines are responsible 
for several processes including insulin sensitivity, 
regulation of lipid metabolism, glucose homeostasis, 
food intake regulation and inflammatory 
responses(10). Omentin is a novel described 
adipokine which almost released from visceral 
adipose tissue and has a molecular mass of 34 
kDa(11). Omentin was first discovered in 2001 while 
plays a substantial role in defense mechanisms in the 
intestinal against harmful bacteria(12). There are two 
types of omentin, omentin-1 and omentin-2. 
Although omentin-1 is the most circulating form of 
omentin in blood(13). There is some evidence that 
serum omentin-1 level is decreased in obesity and its 
related disease such as insulin resistance, type 2 
diabetes (14-17). In vitro studies have shown that 
recombinant omentin-1 enhances glucose uptake in 
adipocytes through activation of Akt signaling(9). 
Recent experiments suggest that omentin-1 play an 
important role in angiogenesis through Akt signaling 
pathway and hyper activation of Akt signaling is 
associated with cancer pathogenesis(18, 19). 
Overexpression of omentin-1 in some cancers 
including malignant pleural mesothelioma and 
colorectal cancer has been reported (20-22). The aim 
of this study was to compare serum omentin-1 levels 
in postmenopausal breast cancer patients with 
healthy controls. To our knowledge this is the first 
study investigating omentin-1 levels in breast cancer 
patients. 
Methods 
Our study population included 30 newly 
diagnosed invasive breast cancer patients (stage IB) 
referred to ayatollah khansari hospital, Arak, I.R.Iran 
and 30 healthy women (control group). None of the 
patients received adjuvant chemotherapy or 
radiotherapy before sample collection. Healthy women 
were collected from participants in breast screening 
program. Inclusion criteria in both groups were as 
follows: postmenopausal women aged 45 to 70 years, 
BMI within the range of 18.5–25 kg/m2 and without 
any special diet. Exclusion criteria in both groups were 
as follows: aged below45 and above  70 years, BMI 
within the range below 18.5and above 25 kg/m2, 
special diet, menopausal women, smoking and any 
other metabolic diseases. As BMI may change 
omentin-1, so other exclusion criteria in both groups 
were BMI below 18.5 and above 25 kg/m2,   Blood 
samples were collected from all participants and 
centrifuged at 3000 rpm for 5 minutes. Serum samples 
were stored at -70 degrees until analysis. Serum 
omentin-1 concentrations were measured by human 
Elisa kit (Bioassay technology laboratory, Shanghai, 
China) with a measurement range of 2-600 ng/L, 
sensitivity of 1.03 ng/L. The Intra-assay CV and Inter-
assay CV were less than 8 and 10%, respectively. 
Informed consent obtained from all subjects before 
participating in the study. It should be noted the Ethics 
Committee of Arak University of Medical Sciences 
approved the study. 
Statistical Analysis. Statistical analysis were 
performed with SPSS version 16.0, data were 
presented as mean ± SD. Student T-test was used to 
compare the case and control groups in a parametric 
way. Two –tailed test, a p value of less than 0.05 were 
considered as statistically significant. 
Results 
This study was performed with 30 newly 
diagnosed invasive breast cancer patients stage IB 
(Group 1) and 30 female control subjects (Group 2). 
All subjects were postmenopausal married women 
which were non-smokers and non-drinkers. 
Furthermore, patients group had no other diseases. The 
mean age of case and control groups was 54.3±8.3 and 
50.3±3.2, respectively. The demographic information 
of the groups were compared and shown in Table 1. 
Patients had a mean body mass index of 24.4± 
0.6 versus 23.4 ± 1.5 of control group. The omentin-1 
levels in the control group were significantly higher 
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than those in the patients group (108.8 ± 65.4 ng/ml 
vs. 73.1 ± 29.7 ng/ml). We also demonstrated the 
negative correlation of Omentin-1 with BMI in both 
groups (p=0.005), however we did not find any 
association between age and serum omentin-1 levels. 
The serum omentin-1 level and BMI of the groups 
were compared and shown in Table 2. 
Discussion 
The association between obesity and cancer 
has been reported by several studies (21-25). 
Although the exact mechanism is unclear but 
adipocytokines such as omentin-1 considered as one 
possible mechanism linking obesity and cancer. 
Measurement of their serum levels may be early 
diagnostic markers for several types of cancer. 
Omentin-1 is a recently discovered adipokine which 
is inversely correlated with BMI and type 2 diabetes 
(26, 27).  
In our study, serum omentin-1 level of breast 
cancer group was significantly lower than the control 
group (p<0.05). Furthermore, significant inverse 
association between serum omentin-1 levels and BMI 
was observed (p<0.05), however there was no 
association between age and omentin-1 levels 
(p=NS). It has been reported that there is an inverse 
association between circulating omentin-1 levels 
with proinflammatory cytokines such as TNF-α and 
IL-6 and also omentin-1 levels reduced in synovial 
fluid of patients with rheumatoid arthritis (17, 28). It 
has been shown that circulating omentin-1 level in 
patients with prostate cancer is higher than patients 
with benign prostatic hyperplasia, however there was 
no association between omentin-1 levels with cancer 
invasiveness (23). In another study serum omentin-1 
level of patients with colorectal cancer was 
significantly higher than the control group and some 
studies indicated effect of omentin-1 on angiogenesis 
through Akt signaling pathway. It has been shown 
activation of Akt signaling play a critical role in 
progression of colorectal cancer through increasing 
cell proliferation and prevent apoptosis (18, 19, 21). 
However, we have not been able to confirm their 
results but in agreement with our findings, another 
study have shown lower serum omentin-1 levels in 
patients with renal cell cancer than the control group 
(24). There is some evidence that shown treatment 
with omentin-1 induced apoptosis in hepatocellular 
carcinoma cells and unregulated p53 and p21 levels. 
Moreover treatment with omentin-1 led to increasing 
protein bax/bcl2 ratio and activation of caspase-3 
signaling pathway(25).  
There is controversy in the correlation between 
serum omentin-1 levels with cancer and these different 
results might be due to different study population, type 
of cancer, cancer treatment such as chemotherapy and 
radiation therapy or other unknown factors that may 
influence omentin-1 level. There is also contradictory 
evidence about omentin-1 levels and BMI. Some 
studies have reported inverse association between 
omentin-1 levels and BMI but were similar between 
obesity and lean groups in another study(26, 29). In 
the current study we found that patients with breast 











High Bachlor Primary 
positive negative 
case 54.3 ± 
8.3 
0% 10% 90% 100% 80% 0% 17% 83% 
control 50.3 ± 
3.2 
10% 80% 10% 100% 47% 0% 7% 93% 
 
Table 2. The comparison of serum omentin-1 level and BMI between Breast Cancer Patients and control group. 
 
Groups  Number of 
Subjects 
Mean of BMI ± SD 
(Kg/m2) 
Mean of omentin-1 ± SD 
(ng/ml) 
P Value 
case 30 24. 4 ± 0.6 73.1 ± 29.7  0.009 
control 30 23.4 ± 1.5 108.8 ± 65.4  
BMI= Body Mass Index.  P value of < 0.05 were considered as statistically significant 
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cancer had lower circulating levels of omentin-1 in 
comparison with healthy subjects and there is 
significant negative association between omentin-1 
levels and BMI, but no association was observed 
between omentin-1 levels and age.  
Conclusion 
Relatively small sample size was the major 
limitation of the present study, so further study with 
larger sample and more precise selection of study 
population is required to evaluate serum omentin-1 
levels in breast cancer patients and compare with 
healthy controls. In conclusion, low serum omentin-1 
level might be associated with creation of breast 
cancer. Further investigations are required to find the 
relation and detailed mechanisms of omentin-1 in 
breast cancer development. 
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